Studies published in the latter years have shown that the system integrated by the receptor activator of nuclear factor kappa B (RANK) and its ligand, RANKL, may have a role in breast cancer oncogenesis (reviewed in [4]). This evidence concerns the gene TNFRSF11A and breast carcinoma.